Immuneering Corporation (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company developing oncology therapies using its proprietary Deep Cyclic Inhibition platform. Our lead asset, atebimetinib (IMM-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK in active Phase 2 and Phase 3 (MAPKeeper 301) clinical trials in pancreatic cancer and RAS-mutant non-small cell lung cancer, as well as additional solid tumor programs. We are committed to delivering transformative treatments to patients with limited options through rigorous science and a collaborative, mission-driven culture. The Vice President will lead company-wide translational medicine, clinical biomarker, bioanalytical, and companion diagnostic strategy across the portfolio. This role will integrate mechanistic biology, PK/PD, immunogenicity, and fit-for-purpose assay development to support dose selection, patient stratification, regulatory interactions, and data-driven advancement from IND-enabling studies through clinical development.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Executive
Education Level
Ph.D. or professional degree